CTOs on the Move

Scholar Rock

www.scholarrock.com

 
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Lisa Wyman
Chief Technical and Quality Officer Profile

Funding

Scholar Rock raised $36M on 01/04/2016
Scholar Rock raised $47M on 01/03/2018
Scholar Rock raised $205M on 06/17/2022

Similar Companies

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.

Biota Pharmaceuticals

Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 and 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.

Comprehensive Blood and Cancer Center

CBCC has treated over 75,000 patients since we first opened. We have continually expanded and have earned the recognition as the largest free standing, privately held cancer center in the nation. While our motivation has always been to offer the finest care available, our story starts in a small office in 1984. Dr. Ravi Patel opened a 1200 square foot cancer clinic as a way to bring his vision of providing cancer patients with specialized medical and emotional care to Bakersfield. In the years since, CBCC has changed in many ways, but the purpose has always remained the same—we believe you shouldn`t have to travel the state for state-of-the-art cancer care.

Ansata Therapeutics

Ansata Therapeutics is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow`s industrial biosolutions, improving our customers' business and the use of our planet`s resources.